Nonhistone Lysine Methylation as a Protein Degradation Signal

Nicholas A. Lehning  
*Boise State University*

Brad E. Morrison  
*Boise State University*

Publication Information  
Lehning, Nicholas A. and Morrison, Brad E. (2022). Nonhistone Lysine Methylation as a Protein Degradation Signal. *Journal of Chemistry, 2022*, 1969299. [https://doi.org/10.1155/2022/1969299](https://doi.org/10.1155/2022/1969299)
Review Article

Nonhistone Lysine Methylation as a Protein Degradation Signal

Nicholas A. Lehning and Brad E. Morrison

1Biomolecular Ph.D. Program, Boise State University, Boise 83725, ID, USA
2Department of Biological Sciences, Boise State University, Boise 83725, ID, USA

Correspondences should be addressed to Brad E. Morrison; bradmorrison@boisestate.edu

Received 13 January 2022; Accepted 24 February 2022; Published 10 March 2022

Academic Editor: Mohd. Sajid Ali

Copyright © 2022 Nicholas A. Lehning and Brad E. Morrison. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Protein degradation is a fundamental feature of cellular life, and malfunction of this process is implicated in human disease. Ubiquitin tagging is the best characterized mechanism of targeting a protein for degradation; however, there are a growing number of distinct mechanisms which have also been identified that carry out this essential function. For example, covalent tagging of proteins with sequestosome-1 targets them for selective autophagy. Degradation signals are not exclusively polypeptides such as ubiquitin, NEDD8, and sequestosome-1. Phosphorylation, acetylation, and methylation are small covalent additions that can also direct protein degradation. The diversity of substrate sequences and overlap with other pleiotropic functions for these smaller signaling moieties has made their characterization more challenging. However, these small signals might be responsible for orchestrating a large portion of the protein degradation activity in the cell. As such, there has been increasing interest in lysine methylation and associated lysine methyltransferases (KMTs), beyond canonical histone protein modification, in mediating protein degradation in a variety of contexts. This review focuses on the current evidence for lysine methylation as a protein degradation signal with a detailed discussion of the class of enzymes responsible for this phenomenon.

1. Introduction

Protein degradation is a critical function for regulating signaling and removal of dysfunctional or misfolded proteins. There are two canonical methods by which this occurs. The ubiquitin/proteasome system (UPS) is the most well-described while the second is autophagy, which can be further distinguished as macroautophagy, microautophagy, or chaperone-mediated autophagy. The importance of these processes is illustrated by protein aggregation and other maladies that occur subsequent to the failure of protein turnover machinery. Many diseases feature protein aggregation as their hallmark, and it is reasonable that this could result from aberrant protein degradation as these are often shown to be linked [1, 2].

Similarly, protein degradation during cellular differentiation is the key to the changing of cellular identity. This process, though, requires that the cell target large numbers of proteins for degradation as global proteome turnover occurs. This dictates a few key requirements that would be necessary for an effective global degradation signal including that it be small and energetically inexpensive, unrestricted by sequence, and paired with an enzyme whose dysfunction is linked to disorders that include aberrant cell differentiation. One potential solution to the problem is lysine methylation.

Nonhistone lysine methylation is a post-translational modification that has garnered increased attention over recent years. While histone methylation has been well-studied since its discovery in 1964, nonhistone substrates for lysine methylation have begun to be identified of late [3, 4]. The enzymes responsible for the methylation of lysine residues are termed lysine methyltransferases (KMTs), and those that remove them are termed lysine demethylases (KDMs). The amine group that is characteristic of lysine residues can accept up to three methyl groups (Figure 1). This is an interesting alteration to the chemical state of lysine in that the positively charged side chain accepts between one and three hydrophobic groups that reside in close proximity to the positive charge. This creates a diametric epitope that could be readily discriminated by the cell. In fact, a variety of
proteins that can recognize methylated lysines have been identified [5–7]. These methyl-lysine-binding proteins are specific to the number and position of methyl groups added to a lysine residue, making each its own distinct signal. The addition of methyl groups to lysine residues has been shown to impact protein-protein interactions, protein-DNA interactions, and protein stability [8–13]. A number of enzymes exist that have been shown to perform mono-, di-, and trimethylation of lysine residues (Table 1). While most of these enzymes are canonically histone methylators, many of them have overlapping function as nonhistone methylators as well [48].

2. Methylation of Nonhistone Proteins

Investigation of proteome methylation has generally been centered on histone modification. This is likely due to the challenges associated with the identification of methylation events using common methods (e.g., western blotting). Methylation results in small changes to mass and no alteration of charge making them difficult to observe. This feature also reduces the numbers of antibody reagents that can specifically recognize this post-translational modification (PTM). When considering nonhistone proteins, the relative low abundance of methylations when compared to histone methylation also presents a challenge. Enrichment techniques have allowed for the application of a few analytical methods for identifying methylated proteins. Mass spectrometry is the most widely used method because when paired with enrichment steps, it can identify not only the presence of methylation but also the nature of methylation (mono-, di-, or tri-) [49, 50]. Chemical enrichment has also enabled the application of affinity tagging for labeling lysine methyltransferase substrates (e.g., bioorthogonal profiling and click labeling) [51–53]. These techniques have led to the identification of a number of nonhistone lysine methyltransferase targets.

Nonhistone lysine methylation is a relatively new field, but it is fast becoming increasingly apparent that this post-translational modification plays a role in cell signaling, particularly within the context of cancer [29, 54]. A central example of this is p53. The tumor suppressor has recently been identified as a substrate for SETD7-mediated methylation [55]. It is important to note that p53 methylation by SETD7, specifically at K372, prevents the addition of other PTMs that inhibit p53 activity [56–59]. Methylation of p53 is site- and context-specific with regard to protein function and stability. Both methylation by SETD7 [55] and demethylation by KDM4A [60] alter p53 stability.

Another protein exhibiting regulation by regulatory methylation is β-catenin. β-catenin is involved in a variety of cellular activities including proliferation, while its dysfunction has been well characterized in tumorigenesis. Methylation of β-catenin has effects on stability, translocation, and activity as a transcriptional regulator [61–63]. Other nuclear targets of nonhistone lysine methylation include RB transcriptional corepressor 1, E2F1, HIF1, retpin, FOXO3, NFKB complex components, and ARTD1 [64–70]. In addition, there have been several other nuclear proteins (nonhistone) identified as targets that play a wide variety of roles in within the cell [71]. Adding complexity is the fact that lysine methylation occurs across the three states: mono-, di-, and trimethylation. Therefore, understanding these individual PTMs in the context of specific signaling events as they relate to protein degradation could inform novel therapeutic approaches.

3. Lysine Methyltransferases

There is a wide spectrum of enzymes capable of catalyzing the addition of methyl groups to lysine residues. As previously discussed, the majority of them perform their function on histones, but many have nonhistone substrates. In line with this notion, the vast majority of these proteins are localized to the nucleus. A select few, though, are localized to, and active in the cytosol.

Lysine methyltransferases exist in one of two superfamilies: the SET-domain containing superfamily and the
β-strand enzymes. The SET-domain superfamily (55 human enzymes) functions primarily on histones with some members acting on both histone and nonhistone proteins. However, only a markedly small portion of function is on nonhistone proteins. Nearly half of the SET-domain members are orphans (substrates unknown). The β-strand superfamily contains 125 enzymes and is not lysine-specific nor is protein-specific. This group as a whole can methylate several different amino acids as well as nucleic acids [72].

SET-domain lysine methyltransferases that are able to perform nonhistone methylations are EZH1, EZH2, EHMT1, EHMT2, NSD1, SETD3, SETD4, SETD6, SETD7, SETD9, SETMAR. It is worthwhile to point out that a few of these (SMYD3, SETD3, and SETD4) not only have nuclear nonhistone targets but also nonhistone targets in the cytosol [74–76]. This is notable due to the fact that KMTs are largely associated with the nuclear localization and activity. This also supports a widespread role of lysine methylation as a degradation signal since most of the cellular protein content is housed in the cytoplasm, making non-nuclear KMTs needed for targeting large swaths of the proteome.

SET-domain KMTs have been shown to be clinically relevant. For example, ASH1L is linked to fascioscapulohumeral muscular dystrophy [77]. MLL (or KMT2a), SUV420H1 (KMT5b), and MLL5 (KMT2e) have all been linked to autism [78–80]. Numerous families including the PRDMs, SETDs, and SMYDs contain members with associations to a wide variety of cancers. The clinical significance of SET-domain KMTs along with their ability to methylate both histone and nonhistone targets in the nucleus and the cytosol make them an important line of future inquiry as well as potential therapeutic targets.

### Table 1: Enzymes with lysine-methylating activity. The enzymes in the SET-domain family and the β-strand family that are active in lysine methylation. Also listed are the known methylation states each enzyme is capable of producing. Many lysine-methylating enzymes have disputed function, and the β-strand family is still being investigated in eukaryotes.

| Gene name | Superfamily | Lysine methylation | Reference |
|-----------|-------------|---------------------|-----------|
| EZH1/KMT6B | SET-domain | Mono, di, tri | [14, 15] |
| EZH2/KMT6A | SET-domain | Mono, di, tri | [16] |
| EHMT1/ KMT1D | SET-domain | Mono, di | [17] |
| EHMT2/ KMT1C | SET-domain | Mono, di, tri | [18] |
| NSD1/KMT3B | SET-domain | Mono, di | [19] |
| NSD2 | SET-domain | Mono, di | [20] |
| NSD3 | SET-domain | Mono, di | [20] |
| SETD1A | SET-domain | Mono, di, tri | [21] |
| SETD1B | SET-domain | Mono, di, tri | [22] |
| SETD4 | SET-domain | Mono, di, tri | [23] |
| SETD6 | SET-domain | Mono | [24] |
| SETD7 | SET-domain | Mono, di | [25] |
| SETD9 | SET-domain | Mono, di | [25] |
| KMT5A | SET-domain | Unknown | [26] |
| SMYD2 | SET-domain | Mono, di | [27, 28] |
| SMYD3 | SET-domain | Mono, di, tri | [29] |
| SMYD5 | SET-domain | Unknown | [30] |
| SETMAR | SET-domain | Mono, di, tri | [30] |
| ASH1L/ KMT2H | SET-domain | Di, tri | [28] |
| DOT1L | SET-domain | Mono, di, tri | [31] |
| MLL | SET-domain | Mono, di, tri | [32] |
| MLL2 | SET-domain | Mono, di, tri | [33] |
| MLL3 | SET-domain | Mono, di, tri | [31] |
| MLL4 | SET-domain | Mono, di, tri | [34] |
| MLL5 | SET-domain | Unknown | [35] |
| SUV39H1 | SET-domain | Di, tri | [36] |
| SUVR2H1 | SET-domain | Di, tri | [37] |
| SUVR42H1 | SET-domain | Di, tri | [38] |
| SUVR42H2 | SET-domain | Di, tri | [38] |
| PRDM-17 | SET-domain | Disputed or unknown | [39] |
| CAMKMT | β-strand | Tri | [40] |
| VCPKMT | β-strand | Tri | [41] |
| EEF1-AKMT1 | β-strand | Tri | [42] |
| EEF2KMT | β-strand | Tri | [43] |
| METTL10 | β-strand | Mono, di, tri | [44] |
| METTL20 | β-strand | Tri | [45] |
| METTL21A | β-strand | Tri | [46] |
| METTL22 | β-strand | Unknown | [47] |
4. Evidence for Lysine Methylation as a Degradation Signal

Lysine methylation is capable of inducing numerous effects depending on the site and the protein. We have discussed changes to protein-protein interactions as well as changes to protein-DNA interactions. Perhaps the most interesting downstream effect of lysine methylation is destabilization of the protein target. There are instances where methylations at different sites can either induce degradation or even inhibit ubiquitination and, thereby, increase stability [81]. Both the positive and negative regulation has been demonstrated to occur, as well as the three different methylation states having differential effects.

DNMT1, a major DNA methyltransferase, exhibits both positive and negative regulation of stability by lysine methylation. If the K142 residue of DNMT1 is methylated, the recognition complex determines the outcome. PHF20L1 contains an MBT domain that can bind to this methylation side and prevent ubiquitin ligases from acting, leading to inhibition of the degradation process [82]. Conversely, if L3MBTL3 binds the same methylation site, ubiquitin ligases are recruited and DMNT1 is degraded [83]. This careful interplay of lysine methylation and recognition proteins determines the fate of DNMT1 and may represent broader paradigm for the investigation of other proteins that may have similar duality.

Many other proteins have been reported to be degraded upon lysine methylation. FOXO1 is a well-studied example. It has been shown that methylation of FOXO1 by G9a (EHMT2) leads to increased interaction with the E3 ubiquitin ligase SKP2 while also decreasing the protein’s stability [65]. Similarly, lysine methylation has shown to have negative effects on the stability of proteins such as p53 and AR [65, 84]. The NFκB complex component RelA is degraded in response to methylation by Set9 [70]. Another protein whose degradation is mediated by lysine methylation is the transcription factor E2F1. Multiple post-translational modifications act in tandem on E2F1 to stimulate degradation. When K185 is methylated, it prevents the acetylation and phosphorylation at a few positions far from K185 while inducing ubiquitination and, in turn, degradation [65]. These changes in stability are widely accepted to originate from one of a few sources including disruption of charge-stabilized regions of the protein leading to misfolding or unfolding, recruitment of unfolding chaperones, or direct proteasome targeting.

5. Summary and Future Perspectives

As our knowledge base regarding KMTs and lysine methylation expands, so does the breadth of roles this PTM plays within the cell. It has become clear the lysine methylation is not limited to histones, nor is it limited to nuclear roles. This is evidence that lysine methylation can instigate a multitude of cellular effects beyond the assembly of heterochromatin. In particular, target destabilization is an important function with growing interest. In considering the potential for lysine methylation to constitute a degradation signal, the current understanding of the PTM’s ability to induce misfolding or direct proteasome targeting becomes increasingly notable. Lysine methylation satisfies the qualifications of being both unbound by amino acid sequence, unlike pathways relying upon consensus sequences, and relatively small and energetically inexpensive to deliver, unlike ubiquitination. It is possible that protein destabilization and/or recruitment of E3 ligases is the mechanism by which lysine methylation acts as a panproteomic degradation signal. While this line of thinking is interesting, it has yet to be reported. As discussed in this review, there have been major advances in our understanding of nonhistone lysine methylation. Still, questions remain as to whether alterations to KMTs associated with nonhistone methylation lead to aberrant protein aggregation on a broader scale or with direct human disease relevance. Such evidence would directly signify the physiological importance of protein degradation through lysine methylation.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

NAL and BEM wrote and edited this manuscript.

Acknowledgments

This work was supported by the National Institute of Neurological Disorders and Stroke (grant R15NS096702) of the National Institutes of Health, the Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences COBRE program (grants P20GM103408 and P20GM109095), and the Biomolecular Research Center at Boise State University.

References

[1] T. A. Thibaudneau, R. T. Anderson, and D. M. Smith, “A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers,” Nature Communications, vol. 9, no. 1, p. 1097, 2018.
[2] A. Ciechanover and Y. T. Kwon, “Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies,” Experimental & Molecular Medicine, vol. 47, no. 3, 2015.
[3] K. Murray, “The occurrence of ie-N-methyl lysine in histones,” Biochemistry, vol. 3, no. 1, pp. 10–15, 1964.
[4] K. K. Biggar and S. S.-C. Li, “Non-histone protein methylation as a regulator of cellular signalling and function,” Nature Reviews Molecular Cell Biology, vol. 16, no. 1, pp. 5–17, 2015.
[5] M. V. Botuyan, J. Lee, J. M. Ward et al., “Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Cbr2 in DNA repair,” Cell, vol. 127, no. 7, pp. 1361–1373, 2006.
[6] Y. Huyen, O. Zgeib, R. A. DiTullio et al., “Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks,” Nature, vol. 432, pp. 406–411, 2004.
[7] J. Kim, J. Daniel, A. Espejo et al., “Tudor, MBT and chromo domains gauge the degree of lysine methylation,” EMBO Reports, vol. 7, no. 4, pp. 397–403, 2006.
[8] J. Huang, J. Dorsey, S. Chuikov et al., “G9a and glp methylate lysine 373 in the tumor suppressor p53,” *Journal of Biological Chemistry*, vol. 285, no. 13, pp. 9636–9641, 2010.

[9] S. Ko, J. Ahn, C. S. Song, S. Kim, K. Knappzuk-Stwora, and B. Chatterjee, “Lysine methylation and functional modulation of androgen receptor by set9 methyltransferase,” *Molecular Endocrinology*, vol. 25, no. 3, pp. 433–444, 2011.

[10] K. Xu, Z. J. Wu, A. C. Groner et al., “EZH2 oncocgenic activity in castration-resistant prostate cancer cells is polycomb-independent,” *Science*, vol. 338, no. 6113, pp. 1465–1469, 2012.

[11] O. Pless, E. Kowenz-Leutz, M. Knoblich et al., “G9a-mediated lysine methylation alters the function of cCAAT/enhancer-binding protein-β,” *Journal of Biological Chemistry*, vol. 283, no. 39, pp. 26357–26363, 2008.

[12] M. Rodríguez-Paredes and F. Lyko, “The importance of non-histone protein methylation in cancer therapy,” *Nature Reviews Molecular Cell Biology*, vol. 20, no. 10, pp. 569–579, 2019.

[13] D. Levy, “Lysine methylation signaling of non-histone proteins in the nucleus,” *Cellular and Molecular Life Sciences*, vol. 76, no. 15, pp. 2873–2883, 2019.

[14] I. Hidalgo, A. Herrera-Merchan, J. M. Ligos et al., “Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest,” *Cell Stem Cell*, vol. 11, no. 5, pp. 649–662, 2012.

[15] E. Ezkhova, W. -H. Lien, N. Stokes, H. A. Pasolli, J. M. Silva, and E. Fuchs, “EZH1 and EZH2 cogenorh histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair,” *Genes and Development*, vol. 25, no. 2, 2011.

[16] K. H. Yoo and L. Hennighausen, “EZH2 methyltransferase and H3K27 methylation in breast cancer,” *International Journal of Biological Sciences*, vol. 8, no. 1, pp. 59–65, 2011.

[17] M. Tachibana, J. Ueda, M. Fukuda et al., “Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9,” *Genes & Development*, vol. 19, no. 7, pp. 815–826, 2005.

[18] S. Kubiczek, R. J. O’Sullivan, E. M. August et al., “Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase,” *Molecular Cell*, vol. 25, no. 3, pp. 473–481, 2007.

[19] A. K. Lucio-Eterovic, M. M. Singh, J. E. Gardner, C. S. Veerappan, J. C. Rice, and P. B. Carpenter, “Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function,” *Proceedings of the National Academy of Sciences*, vol. 107, no. 39, pp. 16952–16957, 2010.

[20] M. Morishita, D. Mevius, and E. di Luccio, “In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1, and NSD3/WHSC1L,” *BMC Structural Biology*, vol. 14, no. 1, p. 25, 2014.

[21] M. R. Higgs, K. Sato, J. J. Reynolds et al., “Histone methylation by SETD1A protects nascent DNA through the nucleosome chaperone activity of FANCDB,” *Molecular Cell*, vol. 71, no. 1, pp. 25–41, 2018.

[22] D. Brici, Q. Zhang, S. Reinhardt et al., “Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program,” *Development*, vol. 144, no. 14, pp. 2606–2617, 2017.

[23] Y. Zhong, P. Ye, Z. Mei et al., “The novel methyltransferase SETD4 regulates TLR agonist-induced expression of cytokines through methylation of lysine 4 at histone 3 in macrophages,” *Molecular Immunology*, vol. 114, pp. 179–188, 2019.

[24] D. Levy, A. J. Kuo, Y. Chang et al., “Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling,” *Nature Immunology*, vol. 12, no. 1, pp. 29–36, 2011.

[25] K. Fujimaki, T. Oghara, D. L. Morris et al., “SET7/9 enzyme regulates cytokine-induced expression of inducible nitric-oxide synthase through methylation of lysine 4 at histone 3 in the islet β cell,” *Journal of Biological Chemistry*, vol. 290, no. 27, pp. 16607–16618, 2015.

[26] D. K. Choi, Y. K. Kim, S. W. Park et al., “The histone lysine methyltransferase SETD8 regulates angiogenesis through HES-1 in human umbilical vein endothelial cells,” *Scientific Reports*, vol. 10, no. 1, p. 12089, 2020.

[27] D. Boehm, M. Jeng, G. Camus et al., “SMYD2-Mediated histone methylation contributes to HIV-1 latency,” *Cell Host & Microbe*, vol. 21, no. 5, pp. 569.e6–579.e6, 2017.

[28] G. Xu, G. Liu, S. Xiong, H. Liu, X. Chen, and B. Zheng, “The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production,” *Journal of Biological Chemistry*, vol. 290, no. 9, pp. 5414–5423, 2015.

[29] P. K. Mazur, N. Reynoard, P. Khatri et al., “SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer,” *Nature*, vol. 510, no. 7504, pp. 283–287, 2014.

[30] E. M. Michalak and J. E. Visvader, “Disregulation of histone methyltransferases in breast cancer—opportunities for new targeted therapies?” *Molecular Oncology*, vol. 10, pp. 1497–1515, 2016.

[31] M. Mohan, H.-M. Her, Y.-H. Takahashi et al., “Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom),” *Genes & Development*, vol. 24, no. 6, pp. 574–589, 2010.

[32] T. A. Milne, J. Kim, G. G. Wang et al., “Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis,” *Molecular Cell*, vol. 38, no. 6, pp. 853–863, 2010.

[33] M. G. Lee, R. Villa, P. Trojer et al., “Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination,” *Science*, vol. 318, no. 5849, pp. 447–450, 2007.

[34] C. Huisman, Y. A. Kim, S. Jeon et al., “The histone H3-lysine 4-methyltransferase Mll4 regulates the development of growth hormone-releasing hormone-producing neurons in the mouse hypothalamus,” *Nature Communications*, vol. 12, no. 1, p. 256, 2021.

[35] X. Zhang, W. Novera, Y. Zhang, and L.-W. Deng, “MLL5 (KMT2E): structure, function, and clinical relevance,” *Cellular and Molecular Life Sciences*, vol. 74, no. 13, pp. 2333–2344, 2017.

[36] S. Schweizer, C. Harms, H. Lerch et al., “Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 35, no. 10, pp. 1640–1647, 2015.

[37] J. C. Rice, S. D. Briggs, B. Ueberheide et al., “Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains,” *Molecular Cell*, vol. 12, no. 6, pp. 1591–1598, 2003.

[38] K. D. Bromberg, T. R. H. Mitchell, A. K. Upadhyay et al., “The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity,” *Nature Chemical Biology*, vol. 13, no. 3, pp. 317–324, 2017.

[39] T. Pandzic, V. Rendo, J. Lim et al., “Somatic PRDM2 c.4467delA mutations in colorectal cancers control histone
Journal of Chemistry

W. Peters, S. Willnow, M. Duiskens et al., “Enzymatic site-specific functionalization of protein methyltransferase substrates with alkynes for click labeling,” *Angewandte Chemie International Edition*, vol. 49, no. 30, pp. 5170–5173, 2010.

M. Kunizaki, R. Hamamoto, F. P. Silva et al., “The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3,” *Cancer Research*, vol. 67, no. 22, pp. 10759–10765, 2007.

S. Chuikov, J. K. Kurash, J. R. Wilson et al., “Regulation of p53 activity through lysine methylation,” *Nature*, vol. 432, pp. 353–360, 2004.

J. K. Kurash, H. Lei, Q. Shen et al., “Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo,” *Molecular Cell*, vol. 29, no. 3, pp. 392–400, 2008.

J. Luo, F. Su, D. Chen, A. Shiloh, and W. Gu, “Deacetylation of p53 modulates its effect on cell growth and apoptosis,” *Nature*, vol. 408, no. 6810, pp. 377–381, 2000.

L. Liu, D. M. Scollnick, R. C. Trievel et al., “p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage,” *Molecular and Cellular Biology*, vol. 19, no. 2, pp. 1202–1209, 1999.

J. Huang, L. Perez-Burgos, B. J. Placek et al., “Repression of p53 activity by Smyd2-mediated methylation,” *Nature*, vol. 444, no. 7119, pp. 629–632, 2006.

Y. Johmura, J. Sun, K. Kitagawa et al., “SCF Fbx22-KDM4A targets methylated p53 for degradation and regulates senescence,” *Nature Communications*, vol. 7, 2016.

C. Shen, D. Wang, X. Liu et al., “SET7/9 regulates cancer cell proliferation by influencing β-catenin stability,” *The FASEB Journal*, vol. 29, no. 10, pp. 4313–4323, 2015.

X. Deng, R. Hamamoto, T. Voughioulakis et al., “Critical roles of Smyd2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling,” *Oncotarget*, vol. 8, no. 34, pp. 55837–55847, 2017.

M. J. Oudhoff, S. A. Freeman, A. L. Couzens et al., “Control of the hippo pathway by set7-dependent methylation of yap,” *Developmental Cell*, vol. 26, no. 2, pp. 188–194, 2013.

L. A. Saddic, L. E. West, A. Aslanian et al., “Methylation of the retinoblastoma tumor suppressor by SMYD2,” *Journal of Biological Chemistry*, vol. 285, no. 48, pp. 37733–37740, 2010.

H. Kontaki and I. Talianidis, “Lysine methylation regulates EZF1-induced cell death,” *Molecular Cell*, vol. 39, no. 1, pp. 152–160, 2010.

K. Subramanian, D. Jia, P. Kapoor-Vazirani et al., “Regulation of estrogen receptor α by the SET17 lysine methyltransferase,” *Molecular Cell*, vol. 30, no. 3, pp. 336–347, 2008.

Y. Kim, H. J. Nam, J. Lee et al., “Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour angiogenesis,” *Nature Communications*, vol. 7, 2016.

J. S. Lee, Y. Kim, I. S. Kim et al., “Negative regulation of hypoxic responses via induced reption methylation,” *Molecular Cell*, vol. 39, no. 1, pp. 71–85, 2010.

Q. Xie, Y. Hao, L. Tao et al., “Lysine methylation of FOXO3 regulates oxidative stress-induced neuronal cell death,” *EMBO Reports*, vol. 13, no. 4, pp. 371–377, 2012.

X.-D. Yang, B. Huang, M. Li, A. Lamb, N. L. Kelleher, and L.-F. Chen, “Negative regulation of NF-κB action by Set9-mediated lysine methylation of the RelA subunit,” *The EMBO Journal*, vol. 28, no. 8, pp. 1055–1066, 2009.

S. M. Carlson and O. Gozani, “Nonhistone lysine methylation in the regulation of cancer pathways,” *Cold Spring Harbor Perspectives in Medicine*, vol. 6, no. 11, 2016.

S. Lanouette, V. Mengoe, D. Figeyys, and J. F. Couture, “The functional diversity of protein lysine methylation,” *Molecular Systems Biology*, vol. 10, no. 4, p. 724, 2014.

K. Islam, Y. Chen, H. Wu et al., “Defining efficient enzymecofactor pairs for bioorthogonal profiling of protein methylation,” *Proceedings of the National Academy of Sciences*, vol. 110, no. 42, pp. 16778–16783, 2013.

G. Blum, K. Islam, and M. Luo, “Bioorthogonal profiling of protein methylation (BPPM) using an azido analog of S-adenosyl-L-methionine,” *Current Protocols in Chemical Biology*, vol. 5, no. 1, pp. 45–66, 2013.

W. Peters, S. Willnow, M. Duiskens et al., “Enzymatic site-specific functionalization of protein methyltransferase substrates with alkynes for click labeling,” *Angewandte Chemie International Edition*, vol. 49, no. 30, pp. 5170–5173, 2010.
[74] R. Hamamoto, Y. Furukawa, M. Morita et al., “SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells,” *Nature Cell Biology*, vol. 6, no. 8, pp. 731–740, 2004.

[75] X. Cheng, Y. Hao, W. Shu et al., “Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis,” *Journal of Biological Chemistry*, vol. 292, no. 22, pp. 9022–9033, 2017.

[76] J. A. Q. A. Faria, N. C. R. Corrêa, C. de Andrade et al., “SET domain-containing protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation,” *Journal of Cancer Science and Therapy*, vol. 5, no. 2, pp. 58–65, 2013.

[77] D. S. Cabianca, V. Casa, B. Bodega et al., “A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in fshd muscular dystrophy,” *Cell*, vol. 149, no. 4, pp. 819–831, 2012.

[78] H. P. Shulha, I. Cheung, C. Whittle et al., “Epigenetic signatures of autism,” *Archives of General Psychiatry*, vol. 69, no. 3, pp. 314–324, 2012.

[79] S. De Rubeis, Y. He, X. He et al., “Synaptic, transcriptional and chromatin genes disrupted in autism,” *Nature*, vol. 515, no. 7526, pp. 209–215, 2014.

[80] A. H. O’Donnell-Luria, L. S. Pais, V. Faundes et al., “Heterozygous variants in KMT2E cause a spectrum of neurodevelopmental disorders and epilepsy,” *The American Journal of Human Genetics*, vol. 104, no. 6, pp. 1210–1222, 2019.

[81] X.-D. Yang, A. Lamb, and L.-F. Chen, “Methylation, a new epigenetic mark for protein stability,” *Epigenetics*, vol. 4, no. 7, pp. 429–433, 2009.

[82] P. O. Estève, H. G. Chin, J. Benner et al., “Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 13, pp. 5076–5081, 2009.

[83] P. O. Estève, J. Terragni, K. Deepii et al., “Methyllysine reader plant homeodomain (PHD) finger protein 20-like 1 (PHF20L1) antagonizes DNA (cytosine-5) methyltransferase 1 (DNMT1) proteasomal degradation,” *Journal of Biological Chemistry*, vol. 289, no. 12, pp. 8277–8287, 2014.

[84] L. Gaughan, J. Stockley, N. Wang et al., “Regulation of the androgen receptor by SET9-mediated methylation,” *Nucleic Acids Research*, vol. 39, no. 4, pp. 1266–1279, 2011.